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Abstract The human multidrug resistance protein MRP1 
mediates transport of organic substrates conjugated to glu-
tathione, glucuronide, or sulfate. The naturally occurring 
prostaglandins Αχ and A2 can form two diastereomeric 
glutathione S-conjugates, and it has been speculated that these 
might be substrates for MRP1. Here we present evidence that 
polarized MDCKII cells expressing MRP1 cDNA transport 
PGAi-GS to the basolateral side of a cell monolayer, in 
accordance with the lateral localization of human MRP1 in 
these cells. Furthermore, we show that vesicles made from yeast 
cells expressing MRP1 cDNA and from mouse erythrocytes 
(known to contain mrpl) actively accumulate both diastereomers 
of PGA2-GS with a similar efficiency. Recently, we generated 
mice with a homozygous mutant mrpl allele. Uptake of PGA2-
GS in vesicles made from erythrocytes of these mice was 3.2 times 
lower than in wild-type vesicles, but was still significantly above 
background. This residual transport activity was partly inhibited 
by methotrexate and cAMP, whereas mrpl-mediated activity 
was unaffected by these compounds. We conclude that mouse 
erythrocytes contain at least two transport systems for PGA2-
GS. One of these is mrpl ; the other one has not been identified 
yet, but can be inhibited by methotrexate and cAMP. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Membrane proteins belonging to the ATP binding cassette 
(ABC) family of transport proteins play a central role in the 
defense of cells against toxic compounds. After exposure of 
mammalian tumor cells to one single cytotoxic drug, these 
cells can become resistant against a whole range of drugs by 
actively lowering the intracellular drug concentration. This 
phenomenon is known as multidrug resistance (MDR). Two 
human members of the ABC family have been identified that 
can render mammalian tumor cells MDR: the MDR1 P-gly-
coprotein (Pgp [1,2]) and the multidrug resistance protein 
(MRP1 [3,4]). Both transporters were identified because of 
their overexpression in MDR tumor cell lines. 
Whereas Pgp preferentially transports hydrophobic amphi-
pathic compounds, it has been demonstrated in experiments 
with inside-out membrane vesicles that MRP1 is able to trans-
*Corresponding author. Fax: (31) (20) 669 1383. 
port a range of substrates that are conjugated to glutathione 
(GSH), glucuronide, or sulfate [5-11]. Transporters with these 
latter substrate characteristics are known as GS-X pumps [12], 
multispecific organic anion transporters [13], or leukotriene C4 
(LTC4) transporters [14]. The exact mechanism by which 
MRP1 transports anti-cancer drugs has not been elucidated 
yet, as for most of these drugs negatively charged conjugates 
are not known to exist. However, both in vitro and in vivo 
experiments have demonstrated that glutathione is required 
for the transport of these compounds [10,15,16]. 
The excretion of conjugates of endogenous and xenobiotic 
compounds is of importance in detoxification and cellular 
homeostasis. One of the endogenous GS-X conjugates is 
LTC4, which belongs to the cysteinyl leukotrienes that play 
an important role in the inflammatory response [17]. As LTC4 
is a high affinity substrate for MRP1 [5] it was postulated that 
it might be one of the physiologically relevant MRP1 sub-
strates. Indeed, Wijnholds et al. [18] have shown that mice 
homozygous for a mrpl mutant allele, mrpl~l~ mice, have 
an impaired response to an LTC4-mediated inflammatory 
stimulus. 
Another set of naturally occurring molecules that are in-
volved in the regulation of the mammalian defense system 
are the prostaglandins which belong to a class of the cyclic 
20-carbon fatty acids that are synthesized from poly-unsatu-
rated fatty acid precursors in response to external stimuli such 
as cell injury and inflammation. The prostaglandins of the A 
and J class are characterized by the presence of a reactive 
α,β-unsaturated ketone moiety in the cyclopentenone ring. 
Treatment of cells with these molecules leads to numerous 
effects like activation of heat shock transcription factor [19], 
inhibition of viral replication [20], inhibition of the cell cycle 
[21,22], and induction of apoptosis [23]. The α,β-unsaturated 
carbonyl group in PGA and PGJ is susceptible to Michael 
addition reactions with the thiol groups of molecules like glu-
tathione, cysteine and proteins. It has been shown that the 
reaction between GSH and PGA occurs efficiently both 
chemically and by the mediation of glutathione 5-transferases 
(GSTs [24-26]) and that two diastereomers can be formed 
[25]. Conjugation of prostaglandins with GSH may result in 
inhibition of their mode of action [27,28], and it has been 
speculated that these conjugates are substrates for MRP1 
[12,26], but this has not been demonstrated directly. Recently, 
we have established assay systems to study some of the trans-
port characteristics of MRP1 [11,18,29,30]. Here we show that 
PGA-GS is transported by MRP1 by in vitro uptake experi-
ments with inside-out vesicles and by transport experiments 
with polarized MDCKII cells transduced with a retrovirus 
containing MRP1 cDNA. 
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2. Materials and methods 
2.1. Materials 
[5,6(n)-3H]Prostaglandin Ex (PGEi; 43 Ci/mmol), and [14C]etha-
crynic acid (EA; 15 mCi/mmol) were obtained from Amersham In-
ternational, Little Chalfont, UK. [35S]Glutathione (GSH; 57.5 Ci/ 
mmol) was obtained from Dupont, Den Bosch, The Netherlands. 
The radioactive conjugate of EA was synthesized from [14C]EA and 
glutathione as described [11]. [3H]PGAi was freshly prepared from 
[3H]PGEi by acid-catalyzed dehydration as previously described 
[31]. The glutathione R- and S-diastereomers of PGA2 were synthe-
sized by incubating [35S]GSH (0.5 mM) and PGA2 (5 mM) in a 50 mM 
K-phosphate buffer (pH 8.0) for 60 min at 25°C. Purification of the 
conjugates was performed by HPLC using a Zorbax C18 
(250x4.6 mm) column. The solvent program started isocratically at 
1 ml/min with 50 mM NH4Ac (pH 3.4), acetonitrile (75:25, v/v) for 
30 min, followed by a linear gradient to 50% acetonitrile in 30 min. 
Peak detection was performed at 200 nm and radioactivity was de-
tected using on-line radiochemical detection. Peak fractions were col-
lected on C02(s) and freeze-dried. After freeze-drying the fractions 
were redissolved in TS buffer (250 mM sucrose, 10 mM Tris-HCl, 
pH 7.4) and stored at —20°C. Rechromatography of the purified 
products showed that they were stable under these conditions. The 
purity of the R- and S-stereoisomers was 99% and 91%, respectively. 
Methotrexate (Emethexate) was from Pharmachemie (Haarlem, The 
Netherlands), and other chemicals were from Sigma, unless stated 
otherwise. 
2.2. Cell lines 
The kidney-derived MDCK cell line strain II (MDCKII [32]) was 
cultured in Dulbecco's modified Eagle medium with 10% fetal calf 
serum. A SaK-Notl DNA fragment containing the complete predicted 
MRP1 open reading frame (pJ3Q-MRPl [33]) was inserted in the 
retro viral vector pCMV-neo [34]. Transfection of the retroviral pack-
aging cell line Phoenix [35] and subsequent transduction of the 
MDCKII cells were exactly as described [31]. 
2.3. Transport assays in MDCKII cells 
Export of [3H]PGAi-GS in MDCKII cells was determined by wash-
ing cells in Hanks' balanced salt solution (HBSS; 5.6 mM glucose, 
10 mM HEPES, 5.4 mM KC1, 143 mM NaCl, 1.3 mM CaCl2, 0.4 mM 
MgS04 , 0.5 mM MgCl2, 0.42 mM NaHC0 3 , 0.44 mM KH 2P0 4 , 
0.34 mM Na2HP04 , pH 7.4). 2 ml HBSS containing 2 μΜ [3H]PGA! 
was added to both sides of the monolayer and cells were incubated at 
37°C. Samples (200 μΐ) were taken at various time points and 100 μΐ 
of 4% (v/v) formic acid was added. Subsequently samples were ex-
tracted twice with 300 μΐ ethyl acetate and radioactivity in 200 μΐ of 
the water phase was determined by liquid scintillation counting. 
2.4. Preparation of membrane vesicles and vesicle uptake studies 
Preparation of microsomal vesicles from DTY168 yeast cells trans-
formed with MRP1 cDNA was exactly as described [11,30]. Transport 
of [14C]EA-GS and PGA2-[35S]GS was measured by the rapid filtra-
tion technique using nitrocellulose filters as described before [11,30]. 
Glutathione conjugates of PGAi and PGA2 used in inhibition experi-
ments (Table 1) were made by incubating a mixture of 1 mM pros-
taglandin and 2 mM GSH in 100 mM K-phosphate buffer (pH 7.5) 
for 2 h at 30°C. PGEi, although not giving any GSH conjugate, was 
treated similarly for comparison. 
A mixture of inside-out and inside-in vesicles was prepared from 
freshly isolated blood from wild-type and mrpl~l~ mice as described 
[18,36]. Briefly, 4 mM EDTA was added to the blood samples and 
after centrifugation (1000 Xg, 10 min) erythrocytes were washed three 
times with buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl), and lysed 
in 10 mM Tris-HCl (pH 7.4), containing 1 mM PMSF, leupeptin 
(1 μg/ml, w/v), and aprotinin (1 μg/ml, w/v). Ghosts were centrifuged 
(20000Xg, 10 min), washed five times in 10 mM Tris-HCl (pH 7.4), 
and incubated in 1 mM Tris-HCl (pH 7.4) for 3 h. After centrifuga-
tion (lOOOOOXg, 30 min, SW41 rotor), membranes were resuspended 
in 0.5 ml TS buffer. Vesicles were formed by passing the suspension 
five times through a 25 gauge needle. Vesicles were washed in TS 
buffer and resuspended in the same buffer at a protein concentration 
of approximately 4 μg/μl. After freezing in liquid nitrogen, membrane 
vesicles were stored at —80°C. Uptake of PGA2-[35S]GS diastereomers 
was measured by the rapid filtration method using nitrocellulose filters 
(0.45 μpiι pore size; Schleicher and Schuell). The reaction buffer was 
TS supplemented with 4 mM ATP, 10 mM MgCl2, 10 mM creatine 
phosphate, 100 μg creatine kinase per ml, and the indicated amount of 
substrate. After equilibration at 37°C, 25-50 μg of vesicles were 
added. The final volume was 50 μΐ. Samples (20 μΐ) were taken at 
the indicated time points, diluted with 900 μΐ of ice-cold TS buffer, 
and applied to the presoaked membrane filters. Filters were rinsed 
with 7 ml of TS buffer. In control experiments ATP was omitted. 
Filters were placed in liquid scintillation fluid and radioactivity was 
determined by liquid scintillation counting. 
3. Results 
It has been shown before that P G A i is a potent inhibitor of 
M R P 1 in intact SI lung cancer cells transfected with MRP1 
cDNA, whereas PGEi is not [37]. We therefore examined 
whether prostaglandins or their G S H metabolites were able 
to inhibit the ATP-dependent t ransport mediated by M R P 1 in 
vitro. As assay system we used microsomal vesicles isolated 
from Saccharomyces cerevisiae cells expressing human MRP1 
c D N A (strain DTY168(MRP1) [30]). This yeast strain has a 
disrupted YCF1 gene [38] and therefore a very low endoge-
nous level of GS-X pump activity [30,39]. As substrate we 
used the glutathione conjugate of ethacrynic acid 
([14C]EA-GS). EA-GS is a M R P 1 substrate that gives low 
background binding to nitrocellulose filters in vesicle uptake 
studies and has a relatively low apparent Km value (5 μ Μ 
[11]). In uptake experiments with [14C]EA-GS (0.2 μΜ) we 
did not observe any inhibition by either P G A i , PGA2 or 
P G E i . In the presence of GSH, however, P G A i and P G A 2 
were efficient inhibitors of [14C]EA-GS transport , whereas 
PGEi was not (Table 1). This difference is most likely ex-
plained by the fact that the PGAs can form G S H conjugates, 
whereas PGEi cannot. Under the conditions employed, a hy-
drophilic conjugate between PGAs and G S H was formed as a 
reaction product partit ioned in the aqueous layer after ethyl 
acetate extraction (data not shown). This product has been 
identified before as P G A - G S (see e.g. [24]). 
To characterize the transport of P G A 2 - G S in more detail 
Table 1 
Effect of prostaglandins and glutathione on ATP-dependent up-
take of [14C]EA-GS (0.2 μΜ) into microsomal vesicles from 
DTY168(MRP1) cells 
+ GSH 
+ GSH 
+ GSH 
- G S H 
+ GSH 
+ GSH 
+ GSH 
- G S H 
+ GSH 
+ GSH 
+ GSH 
- G S H 
0.1 μΜ 
1 μΜ 
10 μΜ 
10 μΜ 
0.1 μΜ 
1 μΜ 
10 μΜ 
10 μΜ 
0.1 μΜ 
1 μΜ 
10 μΜ 
10 μΜ 
% of control 
100 ±5 
99 ±2 
65 ±1 
15 
108 ±3 
91 ±3 
48±2 
9 
104 ±3 
98 ±2 
100 
95 ±3 
106 ±1 
DTY168(MRP1) vesicles were incubated at 25°C for 3 min. Prosta-
glandins and GSH were incubated as described in Section 2. Treat-
ment '—GSH' indicates that prostaglandins were incubated in the 
absence of GSH. ATP-dependent uptake was calculated by subtract-
ing values in the absence of ATP from values in the presence of ATP. 
In the control incubation uptake of [14C]EA-GS was 249 ± 15 pmol/ 
mg protein. Values are means of duplicate measurements ± the varia-
tion between measurements. 
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Fig. 1. A: Reversed phase HPLC radioactivity profile of the incubation of PGA2 with glutathione. Incubation and elution were performed as 
described in Section 2. Structures of the PGA2-GS diastereomers are indicated. B: Time-dependent PGA2-[35S]GS uptake in microsomal vesicles 
from DTY168(MRP1) cells. Vesicles were incubated in the presence of 3 μΜ of the R- (squares) or S- (circles) diastereomers. Samples were 
taken at t = 0, 2, 5, and 10 min. Open and solid symbols represent uptake in the presence and absence of ATP, respectively. Experiments were 
carried out in duplicate and variation was within the size of the symbols. 
35S-labeled conjugate was synthesized in vitro. During the 
reaction two diastereomers were formed, which could be sep-
arated from each other by HPLC (Fig. 1A). Vesicles of 
DTY168(MRP1) cells showed time- and ATP-dependent up-
take of both diastereomers (Fig. IB) with similar efficiency. 
To further characterize the transport characteristics of both 
diastereomers of PGA2-GS we analyzed transport in mem-
brane vesicles prepared from mouse erythrocytes. Erythro-
cytes contain MRP1 [40] and by comparing erythrocyte in-
side-out plasma membrane vesicles prepared from wild-type 
and mrpl~l~ mice we have shown recently that mrpl is the 
high affinity EA-GS and dinitrophenyl glutathione (DNP-GS) 
transporter in the erythrocyte plasma membrane [18]. Com-
parison of time-dependent uptake of the PGA2-GS diaster-
eomers in vesicles made from wild-type and mrpl~l~ mice 
showed that uptake was approximately 3.2 times higher in 
wild-type vesicles (Fig. 2A). Under the assay conditions em-
ployed uptake was linear with the protein concentration 
present in the assay (data not shown). The apparent Km value 
for the ATP-dependent uptake in wild-type vesicles yielded a 
value of 0.8-1 μΜ for the S- and the i?-diastereomers of 
PGA2-GS (Fig. 2B). These results indicate that murine mrpl 
transports PGA2-GS in a non-stereoselective way. 
Heasley and Brunton [24] have shown that the cAMP trans-
port from pigeon erythrocytes is inhibited by PGA-GS and 
Saxena and Henderson [41] have described a transport activity 
in human erythrocyte membranes that might be involved in 
the transport of methotrexate (MTX). However, we have not 
been able to detect inhibition of MRP 1-mediated transport by 
cAMP or MTX in in vitro uptake studies using membrane 
vesicles isolated from DTY168(MRP1) yeast cells (data not 
shown). Table 2 shows that MTX and с AMP partially inhib-
ited uptake of a mixture of PGA2-GS diastereomers in vesicles 
made from mrpl~/~ mice, whereas the mrpl-mediated uptake 
was not significantly affected. 
We and others have shown that MRP1 is present in the 
lateral plasma membrane in polarized cells [29,42]. Transport 
of substrates across the apical and basolateral plasma mem-
brane can be distinguished by growing polarized cells as a 
monolayer on microporous membrane filters. On these filters, 
the physical barrier between the apical and basal compart-
ment is formed by the tight junctions formed between the 
cells. In contrast to MRP1, one of the homologs of MRP1, 
MRP2 or cMOAT, is present in the apical membrane [31,43-
45] and we have demonstrated that cMOAT is involved in 
transport of PGAi-GS to the apical side of a monolayer of 
polarized MDCKII-cMOAT cells [31]. To investigate whether 
PGAi-GS is a substrate for MRP1, we retrovirally transduced 
MDCKII cells with human MRP1 cDNA. For detection of 
MRP1 we used the monoclonal antibody (mAb) MRPrl [46]. 
Several clones were identified which contained substantial lev-
els of MRP1 and subsequent immunolocalization experiments 
using confocal laser scanning microscopy demonstrated that 
MRP1 was present in the lateral plasma membrane in these 
cells, confirming the results with another kidney cell line of 
Evers et al. [29] (data not shown). To investigate whether 
PGAi-GS was transported by MRP1, export was measured 
in MDCKII parental and MDCKII-MRP1 cells. Exported 
PGAi-GS was separated from unconjugated PGAi by ethyl 
acetate extraction. By this method we formally cannot exclude 
that we also isolate other polar metabolites, e.g. PGA^S-Cys, 
which can be formed extracellularly by the mediation of γ-glu-
tamyl transpeptidase. Fig. 3 shows that the parental cells 
transported comparable amounts of polar PGAi metabolites 
to both sides of the monolayer. In contrast, transport in the 
Table 2 
Effect of methotrexate and cAMP on ATP-dependent uptake of 
PGA2-[35S]GS uptake into membrane vesicles from erythrocytes 
Treatment 
Control 
Methotrexate 
cAMP 
50 μΜ 
100 μΜ 
250 μΜ 
1 mM 
100 μΜ 
250 μΜ 
500 μΜ 
Vesicles 
wild-type 
100 ±8 
nd 
107 ±8 
nd 
90±6 
114±8 
nd 
118 
mrpl 1 
100 ±5 
61 ±15 
53 ±7 
51 ±6 
33 ±20 
54±5 
50±11 
50± 11 
Plasma membrane vesicles from wild-type or mrpl - / - erythrocytes 
were incubated with a mixture of PGA2-[35S]GS diastereomers 
(8.5 μΜ) in the presence or absence of the indicated compounds. 
Vesicles (8 and 16 μg protein for wild-type and mrpl - ' - , respectively) 
were incubated at 37°C for 10 min. Relative transport rates (% of 
control) were calculated by subtracting the values in the absence of 
ATP from those in the presence of ATP. Means ± variation between 
duplicate measurements are shown. Experiments were repeated with 
two independent batches of vesicles and substrate, nd, not determined. 
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-1.5 -1.0 -0.5 0.0 0.5 
1/[S] μΜ 
Fig. 2. A: Time course of uptake of PGA2-[35S]GS diastereomers into erythrocyte plasma membrane vesicles from wild type and mrpl~l~ 
mice. Membrane vesicles from wild-type and mrpl / _ erythrocytes were incubated in the presence of 3.5 μΜ or 3.9 μΜ PGA2-GS R- (squares) 
or 5- (circles) form, respectively. Samples were taken at t = 0, 2, 5, and 10 min. Open and solid symbols represent uptake in the presence and 
absence of ATP, respectively. Experiments were carried out in duplicate and bars indicate variation between measurements. B: Lineweaver-
Burk plots of the concentration dependence of uptake of PGA2-[35S]GS R- (squares) and S-form (circles). The concentration of substrate was 
in the range of 1-10 μΜ and the incubation time was 5 min. ATP-dependent uptake was calculated by subtracting values in the absence of 
ATP from those in the presence of ATP. 
MDCKII-MRP1 cells was preferentially to the basolateral 
side of the monolayer, whereas transport to the apical side 
was strongly reduced. This basolateral transport activity is in 
accord with the lateral localization of MRP1 in these cells. 
Similar results were obtained with another MDCKII-MRP1 
clone (data not shown). 
4. Discussion 
By using polarized cells expressing MRP1 cDNA and in 
vitro uptake studies we show in this communication that 
MRP1 transports the glutathione S-conjugates of PGAs 
with a relatively high affinity (Km 1 μΜ). Our data are in 
agreement with the previous hypothesis that MRP1 might 
transport these compounds [12,47]. Bogaards et al. [25] dem-
onstrated that PGA-GS conjugates are formed both chemi-
cally and by the mediation of GSTs. Whereas it was observed 
by these authors that GSTs show a striking stereoselectivity 
for the formation of either the S- or the Ä-form of the con-
jugate we show here that MRP1 transports both diastere-
omers with equal efficiency. Furthermore, we present evidence 
that the mouse erythrocyte plasma membrane contains at least 
two transport systems for PGA2-GS, mrpl and a second un-
identified one. In contrast to mrpl, the second transport ac-
tivity is susceptible to inhibition by methotrexate and cAMP. 
PGA is the dehydration product of PGE and several re-
ports indicate that PGAs inhibit the proliferation of cells by 
inducing cell cycle arrest (e.g. [22]) and apoptosis [23]. Intra-
cellularly PGAs are conjugated to GSH which has been sug-
gested to result in the inhibition of its antiproliferative mode 
of action (see [27,28]). Elevated levels of GSH are frequently 
found in tumor cells and these will shift the equilibrium re-
action between PGA and GSH to the formation of conjugates 
that will be subsequently removed from the cell by MRPL 
This suggests that MRP1 protects tumor cells not only by 
transporting cytotoxic drugs, but also by exporting endoge-
nously formed toxic compounds. However, it remains to be 
tested whether in vivo MRP1 or other GS-X pumps play a 
critical role in this process. 
We have shown recently that the high affinity DNP-GS and 
EA-GS transporter in the erythrocyte is mrpl by comparing 
erythrocyte membrane vesicles prepared from wild-type and 
mrpl~/~ mice [18]. However, some residual uptake activity 
was detectable in the m r p l - / - vesicles. This transport activity 
is probably identical to the low affinity erythrocyte GS-X 
pump that has been described before [36,41]. Based on de-
tailed kinetic studies with several organic anion transport in-
MDCKII 
20 40 
time (min) 
750-
500-
250-
0 -
σ' 
MDC 
a' 
:KJI-MRPI 
...i 
,£-·""' 
p' 
20 40 
time(min) 
Fig. 3. Export of pFflPGAj-GS from MDCKII and MDCKII-MRP1 cells. Cells were incubated at 37°C with [3H]PGA! (2 μΜ) in both the 
apical and basolateral compartment and samples were taken at t= 10, 20, 30, 40, and 60 min. Samples were acidified with formic acid and ex-
tracted twice with an equal volume of ethyl acetate. Squares and continuous line: transport to the apical side. Circles and broken lines: trans-
port to the basolateral side. The experiment was performed in duplicate and repeated three times. 
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hibitors Saxena and Henderson [41] concluded that this trans-
porter is most likely homologous to the methotrexate trans-
porter that they identified in L1210 cells [48]. Our results also 
support the presence of a methotrexate transporter in eryth-
rocyte membranes. However, as we could only inhibit 50% of 
the transport activity in m r p l ~ / ~ vesicles we cannot exclude 
that there is a third P G A 2 - G S transporter present in the 
erythrocyte plasma membrane. Based on its high affinity for 
bilirubin ditaurate evidence for the existence of such an addi-
tional transporter was found in human erythrocytes [41]. 
Analysis of data bases with expressed sequence tags has 
shown that besides M R P 1 and c M O A T four other M R P ho-
mologs exist and one of these might be responsible for metho-
trexate or с A M P transport in the erythrocyte [49,50]. It has 
recently been shown that c M O A T can transport methotrexate 
[51], but c M O A T is not present in erythrocytes [36]. M R P 5 is 
a possible candidate for one of the unidentified transport ac-
tivities, as it is ubiquitously expressed in human tissues [50]. 
Experiments are in progress to investigate this possibility. 
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